Dec 11 (Reuters) - Telehealth company Ro said on

Wednesday it will provide access to single-dose vials of Eli

Lilly's ( LLY ) weight-loss drug Zepbound to patients with

obesity.

The company, in partnership with Lilly, will offer the vials

to eligible patients at a self-pay price, Ro said.

In August, Lilly started selling vials of the lowest starter

dose of Zepbound in the United States for $399 for a month's

supply through its direct-to-consumer website.